Physician profile
Muhamed Abubacker
NPI 1639675424
$2,106.15
in general payments reported to CMS, 2019-2025
15 companies · $1,428 in 2025
The $1,428 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $78.84 · 2022: $321 · 2023: $75.74 · 2024: $202 · 2025: $1,428.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,607 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,607.28 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $578.46 | 2022-2025 | Avycaz, Dalvance |
| Amgen INC. | $409.51 | 2025 | Otezla, Krystexxa, Tavneos |
| Ucb, INC. | $188.76 | 2025 | Bimzelx |
| E.R. Squibb & Sons, L.L.C. | $142.37 | 2022-2023 | Camzyos |
| Pfizer INC. | $122.69 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $102.94 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $101.31 | 2022-2025 | Saphnelo, Farxiga |
| Novartis Pharmaceuticals Corporation | $101.27 | 2021-2025 | |
| Janssen Biotech, INC. | $99.00 | 2024 | Tremfya |
| Janssen Scientific Affairs, LLC | $86.70 | 2024 | |
| Mallinckrodt Hospital Products INC. | $71.58 | 2025 | Acthar |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $26.96 | 2022 | |
| Celltrion USA INC. | $26.82 | 2025 | Vegzelma |
| Gotham Surgical Solutions & Devices, INC. | $26.00 | 2025 | |
| Ani Pharmaceuticals, INC. | $21.78 | 2025 | Purified Cortrophin Gel |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Muhamed Abubacker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.